Clinical impact of amyloid PET using 18F-florbetapir in patients with cognitive impairment and suspected Alzheimer’s disease: a multicenter study
Authors:
Open Access
- 4 October 2022
- journal article
- research article
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 36 (12) , 1039-1049
Abstract
Objective: Amyloid positron emission tomography (PET) can reliably detect senile plaques and fluorinated ligands are approved for clinical use. However, the clinical impact of amyloid PET imaging is still under investigation. The aim of this study was to evaluate the diagnostic impact and clinical utility in patient management of amyloid PET using 18F-florbetapir in patients with cognitive impairment and suspected Alzheimer’s disease (AD). We also aimed to determine the cutoffs for amyloid positivity for quantitative measures by investigating the agreement between quantitative and visual assessments. Methods: Ninety-nine patients suspected of having AD underwent 18F-florbetapir PET at five institutions. Site-specialized physicians provided a diagnosis of AD or non-AD with a percentage estimate of their confidence and their plan for patient management in terms of medication, prescription dosage, additional diagnostic tests, and care planning both before and after receiving the amyloid imaging results. A PET image for each patient was visually assessed and dichotomously rated as either amyloid-positive or amyloid-negative by four board-certified nuclear medicine physicians. The PET images were also quantitatively analyzed using the standardized uptake value ratio (SUVR) and Centiloid (CL) scale. Results: Visual interpretation obtained 48 positive and 51 negative PET scans. The amyloid PET results changed the AD and non-AD diagnosis in 39 of 99 patients (39.3%). The change rates of 26 of the 54 patients (48.1%) with a pre-scan AD diagnosis were significantly higher than those of 13 of the 45 patients with a pre-scan non-AD diagnosis (χ2 = 5.334, p = 0.0209). Amyloid PET results also resulted in at least one change to the patient management plan in 42 patients (42%), mainly medication (20 patients, 20%) and care planning (25 patients, 25%). Receiver-operating characteristic analysis determined the best agreement of the quantitative assessments and visual interpretation of PET scans to have an area under the curve of 0.993 at an SUVR of 1.19 and CL of 25.9. Conclusion: Amyloid PET using 18F-florbetapir PET had a substantial clinical impact on AD and non-AD diagnosis and on patient management by enhancing diagnostic confidence. In addition, the quantitative measures may improve the visual interpretation of amyloid positivity.Keywords
Funding Information
- PDRadiopharma Inc.
This publication has 33 references indexed in Scilit:
- Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan InterpretationAmerican Journal of Neuroradiology, 2015
- A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and dispositionMolecular Neurodegeneration, 2014
- Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive DeclineAlzheimer Disease & Associated Disorders, 2013
- Added Diagnostic Value of 11C-PiB-PET in Memory Clinic Patients with Uncertain DiagnosisDementia and Geriatric Cognitive Disorders Extra, 2012
- Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort studyThe Lancet Neurology, 2012
- Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal SubjectsJournal of Nuclear Medicine, 2012
- Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environmentEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 YearsJournal of Neuropathology & Experimental Neurology, 2011
- In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)Journal of Nuclear Medicine, 2010
- “Mini-mental state”Journal of Psychiatric Research, 1975